

Interaction of 2-Aryl-4-cyano-1,3-oxazole-5-sulfonyl Chlorides with Amidines

A. N. Kornienko, S. G. Pil'ov, V. M. Prokopenko, E. B. Rusanov, and V. S. Brovarets

*Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine,
ul. Murmanskaya 1, Kyiv, 02660 Ukraine
e-mail: brovarets@bpci.kiev.ua*

Received June 28, 2012


Abstract—Reaction of 4-cyano-1,3-oxazole-5-sulfonyl chlorides with amidines results in new 7-amino-1,3-oxazolo[5,4-*d*]pyrimidines. Their structure was confirmed by spectral methods and X-ray diffraction analysis.

DOI: 10.1134/S1070363213070165

Recently, we have synthesized 4-cyano-1,3-oxazole-5-sulfonyl chlorides **I** [1], which react with piperidine or morpholine in dioxane in the presence of triethylamine at reflux to afford the corresponding sulfonamides. In this work it is shown that amidines interact originally with compounds **I** to form 7-amino-1,3-oxazolo[5,4-*d*]pyrimidines **V** in 44-60% yields (Table 1).

Synthesis of products **Va–Vk** includes several steps: the initial formation of intermediates **II**, the intramolecular cyclization **II** → **III**, the transformation of the seven-membered ring to the six-membered ring

due to the elimination of sulfur dioxide **III** → **IV**, and the subsequent tautomerization **IV** → **V**. Also it is not improbable that sulfonamides **II** react with another molecule of amidine at the C⁵ atom of the ring or the cyano group followed by the closure of the pyrimidine ring by the nucleophilic substitution of the sulfonyl-amide fragment. However, the fact that 4-cyano-1,3-oxazoles containing sulfamide [1] or arylsulfonyl [2] groups at the atom C⁵ do not react with amidines is an indirect confirmation of the proposed scheme involving an intermediate formation of the seven-membered structure **III**. It is noteworthy that desulfurization of the products proceeds under mild conditions (at 20°C).



R = Ph (**Va, Vh**), 4-MeC₆H₄ (**Vb**), 4-EtC₆H₄ (**Vc, Vi**), 4-MeOC₆H₄ (**Vd, Vj**), 4-FC₆H₄ (**Ve, Vk**), 4-MeC₆H₄S (**Vf**), Me (**Vg**);
Ar = Ph (**Ia, Va–Vg**), 4-MeC₆H₄ (**Ib, Vh–Vk**).

Table 1. Yields, melting points and data of elemental analyses for compounds **V**

Comp. no.	Yield, %	mp, °C	Found, %			Formula	Calculated, %		
			C	H	N		C	H	N
Va	54	251–252	70.95	4.25	19.40	C ₁₇ H ₁₂ N ₄ O	70.82	4.20	19.43
Vb	56	262–264	71.48	4.67	18.59	C ₁₈ H ₁₄ N ₄ O	71.51	4.67	18.53
Vc	60	225–226	72.10	5.02	17.82	C ₁₉ H ₁₆ N ₄ O	72.14	5.10	17.71
Vd	60	244–245	67.89	4.42	17.68	C ₁₈ H ₁₄ N ₄ O ₂	67.92	4.43	17.60
Ve	50	266–267	66.72	3.67	18.18	C ₁₇ H ₁₁ FN ₄ O	66.66	3.62	18.29
Vf	50	254–255	64.67	4.24	16.70	C ₁₈ H ₁₄ N ₄ OS ^a	64.65	4.22	16.75
Vg	44	227–229	63.75	4.48	24.77	C ₁₂ H ₁₀ N ₄ O	63.71	4.46	24.76
Vh	50	303–304	71.50	4.68	18.67	C ₁₈ H ₁₄ N ₄ O	71.51	4.67	18.53
Vi	52	266–267	72.74	5.53	16.89	C ₂₀ H ₁₈ N ₄ O	72.71	5.49	16.96
Vj	52	301–303	68.62	4.80	16.91	C ₁₉ H ₁₆ N ₄ O ₂	68.66	4.85	16.86
Vk	50	299–301	67.40	4.01	17.87	C ₁₈ H ₁₃ FN ₄ O	67.49	4.09	17.79

^a Found, %: S 9.68. Calculated, %: S 9.59.

The target products were isolated in satisfactory yields. This direction of the reaction is apparently due to the formation of a thermodynamically stable pyrimidine ring. It should also be noted that this contraction of the heterocyclic fragment due to sulfur dioxide liberation is well known [3, 4]. However, such transformations are carried out under rigid conditions.

The IR spectra of compounds **Va–Vk** (Table 2) contain the absorption bands of the stretching vibrations of NH₂-groups at 3314–3378 and 3208–3220 cm⁻¹ and the signals of 7-aminooxazolo-[5,4-*d*]-pyrimidines moiety [5]. In the ¹H NMR spectra along with the signals of the protons of aromatic rings and substituents there is a broad singlet of NH₂-group at 7.66–7.87 ppm.

To establish unambiguously the structure of compounds **V** and to consider their spatial structure we carried out XRD analysis of compound **Ve** (see figure).

Values of the bond lengths and bond angles of the central bicyclic moiety are within the expected range and are consistent with the structural formula of the compound. Thus, the bonds themselves are delocalized and have values typical of delocalized structures previously studied, for example, for the related compound containing a similar moiety [6]. The central bicycle is flat, the atoms are out-of-plane only by 0.0044 Å. Phenyl rings C⁶–C¹¹ and C¹²–C¹⁷ are turned

relative to the bicycle by 8.95(8) and 4.99(6)°, respectively. The bond length C⁴–N³ is strongly reduced compared to the value characteristic of the single C–N bonds [1.338(2) Å]. The sum of bond angles at the nitrogen atom of the amino group is 360(2)°, indicating the coupling of the lone electron pair of the nitrogen atom N³ with the π-system of heterocycle. In the crystal the formation is observed of weak intermolecular hydrogen bonds N³–H²...N^{4#1} and N³–H¹...N^{2#2} with the following parameters: N³–H² 0.93(2), N³...N^{4#1} 3.148(3), N³–H²...N^{4#1} 152.3(17)° и N³–H¹ 0.88(2), N³...N^{2#2} 3.059(2), N³–H¹...N^{2#2} 144.7(19)°, respectively, (symbols #1 and #2 denote the atoms that are connected with the basic operations of symmetry $-x + 1, y, -z + 0.5$ и $x, -y, z - 0.5$, respectively).

As compounds **V** are structural analogs of purine bases and among them substances with diverse biological activities were found [7–12], the developed approach to the synthesis of 7-amino-1,3-oxazolo[5,4-*d*]pyrimidines, which well supplements the well-known methods for their preparation [5, 9, 13, 14], deserves further studying, as will be discussed in subsequent reports.

EXPERIMENTAL

The IR spectra were recorded on a Vertex 70 instrument from KBr pellets. The ¹H and ¹³C NMR spectra were obtained on a Bruker Avance DRX-500


Table 2. Spectral data of compounds **V**

Comp. no.	IR spectrum (KBr), ν , cm^{-1}	^1H NMR spectrum (DMSO- d_6), δ , ppm	Mass-spectrum, m/z
Va	3322, 3210 (NH ₂); 1637, 1592, 1392, 1316, 1275, 1130, 1048	7.50–8.37 m (10H, 2C ₆ H ₅), 7.83 br.s (2H, NH ₂)	289 [$M + 1$] ⁺
Vb	3326, 3212 (NH ₂); 1635, 1590, 1393, 1313, 1278, 1129, 1048	2.37 s (3H, CH ₃), 7.29 d, 8.26 d (4H, C ₆ H ₄ , J 8.0 Hz), 7.61 m, 8.15 m (5H, C ₆ H ₅), 7.78 br.s (2H, NH ₂)	303 [$M + 1$] ⁺
Vc^a	3324, 3211 (NH ₂); 1637, 1588, 1395, 1312, 1276, 1130, 1048	1.23 t (3H, CH ₃ , J 7.5 Hz), 2.68 q (2H, CH ₂ , J 7.5, J 1.5 Hz), 7.33 d, 8.28 d (4H, C ₆ H ₄ , J 8.5 Hz), 7.63 m, 8.16 m (5H, C ₆ H ₅), 7.79 br.s (2H, NH ₂)	317 [$M + 1$] ⁺
Vd^b	3326, 3213 (NH ₂); 1634, 1607, 1395, 1304, 1253, 1131, 1048	3.84 s (3H, OCH ₃), 7.04 d, 8.32 d (4H, C ₆ H ₄ , J 8.5 Hz), 7.63 m, 8.15 m (5H, C ₆ H ₅), 7.75 br.s (2H, NH ₂)	319 [$M + 1$] ⁺
Ve^c	3326, 3213 (NH ₂); 1637, 1593, 1395, 1303, 1277, 1131, 1048	7.32 m, 8.40 m (4H, C ₆ H ₄), 7.63 m, 8.15 m (5H, C ₆ H ₅), 7.85 br.s (2H, NH ₂)	307 [$M + 1$] ⁺
Vf^d	3378, 3211 (NH ₂); 1626, 1599, 1346, 1307, 1276, 1133, 1045	2.38 s (3H, CH ₃), 7.29 d, 7.50 d (4H, C ₆ H ₄ , J 8.5 Hz), 7.57 m, 8.05 m (5H, C ₆ H ₅), 7.87 br.s (2H, NH ₂)	335 [$M + 1$] ⁺
Vg	3314, 3220 (NH ₂); 1665, 1599, 1404, 1297, 1274, 1136, 1045	2.44 s (3H, CH ₃), 7.61 m, 8.10 m (5H, C ₆ H ₅), 7.66 br.s (2H, NH ₂)	227 [$M + 1$] ⁺
Vh	3320, 3209 (NH ₂); 1638, 1593, 1391, 1316, 1273, 1129, 1048	2.43 s (3H, CH ₃), 7.44 d, 8.06 d (4H, C ₆ H ₄ , J 8.5 Hz), 7.50 m, 8.37 m (5H, C ₆ H ₅), 7.81 br.s (2H, NH ₂)	303 [$M + 1$] ⁺
Vi	3322, 3208 (NH ₂); 1635, 1596, 1395, 1311, 1275, 1135, 1051	1.20 t (3H, CH ₃ , J 7.5 Hz), 2.39 s (3H, CH ₃), 2.66 q (2H, CH ₂ , J 7.5, J 1.5 Hz), 7.32–8.30 m (8H, 2C ₆ H ₄), 7.76 br.s (2H, NH ₂)	331 [$M + 1$] ⁺
Vj	3323, 3209 (NH ₂); 1635, 1608, 1396, 1306, 1256, 1134, 1050	2.42 s (3H, CH ₃), 3.84 s (3H, OCH ₃), 7.04–8.31 m (8H, 2C ₆ H ₄), 7.71 br.s (2H, NH ₂)	333 [$M + 1$] ⁺
Vk	3326, 3212 (NH ₂); 1637, 1594, 1395, 1304, 1235, 1131, 1050	2.42 s (3H, CH ₃), 7.34–8.39 m (8H, 2C ₆ H ₄), 7.82 br.s (2H, NH ₂)	321 [$M + 1$] ⁺

^a ^{13}C NMR spectrum (DMSO- d_6), δ_{C} , ppm: 15.78, 28.53, 115.03, 126.87, 127.24, 128.26, 128.38, 129.84, 132.14, 135.49, 146.73, 156.70, 158.49, 160.19, 165.78. ^b ^{13}C NMR spectrum (DMSO- d_6), δ_{C} , ppm: 55.77, 114.22, 114.69, 126.90, 127.19, 129.82, 129.94, 130.42, 132.08, 156.65, 158.26, 160.03, 161.67, 165.81. ^c ^{13}C NMR spectrum (DMSO- d_6), δ_{C} , ppm: 115.14, 115.69, 115.86, 126.80, 127.26, 129.84, 130.53, 130.60, 132.20, 134.38, 134.40, 156.72, 158.64, 159.12, 163.15, 165.12, 165.71. ^d ^{13}C NMR spectrum (DMSO- d_6), δ_{C} , ppm: 21.36, 114.00, 126.57, 126.69, 127.10, 129.76, 130.32, 132.03, 135.64, 139.36, 156.46, 157.51, 165.10, 166.82.

spectrometer (500 and 125 MHz, respectively), internal reference TMS. GC-MS spectra were recorded using a high-performance liquid chromatograph-mass spectrometer Agilent 1100 Series equipped with a diode array with a mass selective detector Agilent LC\MSD SL. Parameters of GC-MS analysis: column Zorbax SB-C18 1.18 μm 4.6 \times 15 mm (PN 821975-932); solvent acetonitrile–water (95:5), 0.1% aqueous trifluoroacetic acid, eluent flow 3 ml min^{-1} , injection volume 1 μl ; UV detecting at 215, 254, 285 nm, chemical ionization at atmospheric pressure (APCI), scan range m/z 80–1000. Melting points were measured on a Fisher-Johns instrument.

Single crystal X-ray diffraction analysis of compound **Ve** was performed at room temperature on a Bruker Smart Apex II diffractometer ($\lambda\text{MoK}\alpha$ - radiation, graphite monochromator, θ_{max} 28.1°, crystal size 0.14 \times 0.25 \times 0.30 mm, spherical segment $-25 \leq h \leq 41$, $-9 \leq k \leq 8$, $-16 \leq l \leq 17$). 11022 reflections were collected, 3379 of which were independent (R -factor is 0.0403). The crystals of compound **Ve** are monoclinic, C₁₇H₁₁FN₄O, M 306.3, space group $C2/c$, a 31.366(3), b 7.2159(5), c 10.9413(3) Å, β 103.406(7)°, V 2830.6(4) Å³, Z 8, d_{calc} 1.437, μ 0.103 mm^{-1} , $F(000)$ 1264. The structure was solved by the direct method and refined by the least squares method using



General view of the molecule of compound **Ve**. Main bond lengths and angles: C¹N¹ 1.330(2), C¹N² 1.354(2), C²N² 1.324(2), C²C³ 1.374(3), C³C⁴ 1.397(2), C⁴N¹ 1.357(2), C⁴N³ 1.338(2), C³N⁴ 1.390(2), C⁵N⁴ 1.304(2), C²O¹ 1.373(2), C⁵O¹ 1.386(2) Å; C¹N¹C⁴ 119.79(16), N¹C¹N² 127.19(17), C²N²C¹ 110.31(15), N²C²C³ 129.29(17), C²C³C⁴ 115.59(18), N¹C⁴C³ 117.82(17), O¹C²C³ 107.18(16), C²C³N⁴ 110.50(16), C⁵N⁴C³ 103.49(15), N⁴C⁵O¹ 114.74(16), C²O¹C⁵ 104.09(14), N²C²O¹ 123.53(16), N⁴C³C⁴ 133.89(18)°.

SHELXTL program [15]. For refining 1895 reflections with $I > 2\sigma(I)$ were used {216 refined parameters, 8.8 reflections per one parameter, the weight scheme $\omega = 1/[\sigma^2(\text{Fo}^2) + (0.0517P)^2 + 0.9395P]$ was used, where $P = (\text{Fo}^2 + 2\text{Fc}^2)/3$, the ratio of the maximal (average) shift to the error in the last cycle was 0.001(0.000)}. The extinction was corrected by multiscanning method using SADABS program ($T_{\min}/T_{\max} = 0.9857/0.9697$). All non-hydrogen atoms were anisotropically refined. All CH-hydrogen atoms in the molecule were geometrically placed (*riders*). Their positions and thermal parameters were refined together with positions and thermal parameters of the carbon atoms. The hydrogen atoms at the nitrogen atoms were identified in the difference Fourier syntheses and refined isotropically. Final values of divergence factors are $R_1(F)$ 0.0503, $wR_2(F^2)$ 0.1086 for reflections with $I > 2\sigma(I)$ and $R_1(F)$ 0.1076, $wR_2(F^2)$ 0.1326, GOF 1.032 for all reflections. Residual electron density from the difference Fourier series after the last cycle of refinement is 0.27 and $-0.21 e \text{ \AA}^{-3}$.

A complete set of X-ray diffraction data for compound **Ve** was deposited in the Cambridge Structural Database (CCDC 882263).

2-Aryl-5-methyl(aryl, arylthio)-7-amino-1,3-oxazolo[5,4-*d*]pyrimidines (Va–Vk). A mixture of

0.01 mol of a 4-cyano-1,3-oxazole-5-sulfonyl chloride **I** [1], 0.01 mol of the appropriate amidine hydrochloride, and 0.02 mol of triethylamine in 50 ml of anhydrous tetrahydrofuran was stirred at 20–25°C for 48 h. The precipitate was filtered off, the solvent was removed in a vacuum. The residue was treated with water, filtered off, dried, and purified by recrystallization from acetonitrile.

REFERENCES

- Kornienko, A.N., Pil'ov, S.G., Prokopenko, V.M., and Brovarets, V.S., *Russ. J. Gen. Chem.*, 2012, vol. 82, no. 11, p. 1855.
- Pil'ov, S.G., Brovarets, V.S., Vinogradova, T.K., Golovchenko, A.V., and Drach, B.S., *Russ. J. Gen. Chem.*, 2002, vol. 72, no. 11, p. 1714.
- Abramovitch, R.A., Holcomb, W.D., and Wake, S., *J. Am. Chem. Soc.*, 1981, vol. 103, no. 6, p. 1525.
- Abramovitch, R.A., Kress, A.O., McManus, S.P., and Smith, M.R., *J. Org. Chem.*, 1984, vol. 49, no. 17, p. 3114.
- Ohtsuka, Y., *Bull. Chem. Soc. Jpn.*, 1970, vol. 43, no. 1, p. 187.
- Freeman, F., Scheuerman, R.A., and Ziller, J.W., *Acta Crystallogr. (C)*, 1996, vol. 52, no. 8, p. 2006.
- Bauser, M., Delapierre, G., Hauswald, M., Flessner, T., D'Urso, D., Hermann, A., Beyreuther, B., De Vry, J., Spreyer, P., Reis-smuller, E., and Meier, H., *Bioorg. Med. Chem. Lett.*, 2004, vol. 14, no. 8, p. 1997.
- Martin-Kohler, A., Widmer, J., Bold, G., Meyer, T., Sequin, U., and Traxler, P., *Helv. Chim. Acta*, 2004, vol. 87, no. 4, p. 956.
- Holschbach, M.H., Bier, D., Stusgen, S., Wutz, W., Sihver, W., Coenen, H.H., and Olsson, R.A., *Eur. J. Med. Chem.*, 2006, vol. 41, no. 1, p. 7.
- Jang, M., Lin, Y., De Jonghe, S., Gao, L., Vanderhoydonck, B., Froeyen, M., Rozenski, J., Herman, J., Louat, T., Van Belle, K., Waer, M., and Herdewijn, P., *J. Med. Chem.*, 2011, vol. 54, no. 2, p. 655.
- WO USA Patent no. 057402, 2008.
- WO USA Patent no. 081675, 2010.
- Patil, V.D. and Townsend, L.B., *J. Heterocycl. Chem.*, 1971, vol. 8, p. 503.
- Hurst, D.T., Atcha, S., and Marshall, K.L., *Aust. J. Chem.*, 1991, vol. 44, no. 1, p. 129.
- Sheldrick, G. M., *Acta Crystallogr. (A)*, 2008, vol. 64, no. 1, p. 112.